References
- Aaronson N. K. Quality of life assessment in clinical trials: methodologic issues. Control Clin. Trials 1989; 10(4 suppl)195–208, [CSA]
- Adam T., Koopmanschap M. A., Evans D. B. Cost-effectiveness analysis: can we reduce variability in costing methods?. Int. J. Technol. Assess. Health Care 2003; 19: 407–420, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Addington-Ha U. J., Kalra L. Who should measure quality of life?. Br. Med. J. 2001; 322: 1417–1420, [CSA]
- Avants S K., Margolin A., Sindelar J. L., Rounsaville B. J., Schottenfeld R., Stine S. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am. J. Psychiatry 1999; 156(1)27–33, [PUBMED], [INFOTRIEVE], [CSA]
- Barnett P. G. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 1999; 94(4)479–488, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Barnett P. G., Hui S. S. The cost-effectiveness of methadone maintenance. Mt. Sinai. J. Med. 2000; 67(5-6)365–374, [PUBMED], [INFOTRIEVE], [CSA]
- Bellis D. J. Reduction of AIDS risk among 41 heroin addicted female street prostitutes: effects of free methadone maintenance. J. Addict. Dis. 1993; 12(1)7–23, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Caplehorn J. R. A comparison of abstinence-oriented and indefinite methadone maintenance treatment. Int. J. Addict. 1994; 29(11)1361–1375, [PUBMED], [INFOTRIEVE], [CSA]
- Caplehorn J. R., Dalton M. S., Cluff M. C., Petrenas A. M. Retention in methadone maintenance and heroin addicts' risk of death. Addiction 1994; 89(2)203–209, [PUBMED], [INFOTRIEVE], [CSA]
- Caplehorn J. R., Dalton M. S., Haldar F., Petrenas A. M., Nisbet J. G. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst. Use Misuse 1996; 31(2)177–196, [PUBMED], [INFOTRIEVE], [CSA]
- Caplehorn J. R., Ross M. W. Methadone maintenance and the likelihood of risky needle-sharing. Int. J. Addict. 1995; 30(6)685–698, [PUBMED], [INFOTRIEVE], [CSA]
- Caplehorn J. R., Saunders J. B. Factors associated with heroin users' AIDS risk-taking behaviours. Aust. J. Public. Health. 1993; 17(1)13–17, [PUBMED], [INFOTRIEVE], [CSA]
- Cella D. F., Tulsky D. S. Measuring quality of life today: methodological aspects. Oncology 1990; 5: 29–38, [CSA]
- Creese A., Parker D. Cost Analysis in Primary Health Care: A Training Manual for Programme Managers. World Health Organization, Geneva 1994
- Cummins R. A. Directory of to Measure Quality of Life and Cognate Areas, 2nd ed. School of Psychology, Deakin University, Melbourne 1996
- Dempster M., Donnelly M. Selecting a measure of health related quality of life. Soc Work Health Care 2000; 32(1)45–56, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dimenas E. S., Dahlof C. G., Jern S. C., Wiklund I. K. Defining quality of life in medicine. Scand. J. Prim. Health Care 1990, Suppl 1: 7–10, [CSA]
- Drummond M. F., O'Brien B., Stoddart G. L., Torrance G. W. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford University Press, Oxford 1997
- Flynn P. M., Kristiansen P. L., Porto J. V., Hubbard R. L. Costs and benefits of treatment for cocaine addiction in DATOS. Drug. Alcohol. Depend. 1999; 57(2)167–174, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- French M. T., McGeary K. A. Estimating the economic cost of substance abuse treatment. Health. Econ. 1997; 6(5)539–544, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- French M. T., Salome H., Carney M. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington. Soc. Sci. Med. 2002; 55(12)2267–2282, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gerin P., Dazord A., Boissel J., Chifflet R. Quality of life assessment in therapeutic trials: rationale for and presentation of a more appropriate instrument. Fundam. Clin. Pharmacol. 1992; 6: 263–276, [PUBMED], [INFOTRIEVE], [CSA]
- Giacomuzzi S. M., Riemer Y., Kemmler G., Ertl M., Richter R., Rossler H. [Subjective wellbeing in heroin withdrawal. With methadone the patient feels better]. MMW Fortschr. Med. 2001; 143(37)53, [PUBMED], [INFOTRIEVE], [CSA]
- Giacomuzzi S. M., Riemer Y., Ertl M., Kemmler G., Rossler H., Hinterhuber H. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction 2003; 98(5)693–702, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gold M. R., Siegel J. E., Russel L. B., Weinstein M. C. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York 1996
- Guyatt G. H., Feeny D. H., Patrick D. L. Measuring health-related quality of life. Annals of Internal Medicine 1993; 118: 622–629, [PUBMED], [INFOTRIEVE], [CSA]
- Holder H. D. Cost benefits of substance abuse treatment: an overview of results from alcohol and drug abuse. J. Ment. Health Policy Econ. 1998; 1(1)23–29, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jefferson T., Demicheli V., Mugford M. Elementary Economic Evaluation in Health Care. 2nd Ed. BMJ Books, London 2000
- Jenney M., Campbell S. Measuring quality of life. Arch. Dis. Child. 1997; 77(4)347–350, [PUBMED], [INFOTRIEVE], [CSA]
- Johns B., Baltussen R., Hutubessy R. Programme costs in the economic evaluation of health interventions. Cost Effectiveness and Resource Allocation 2003; 1(1)1, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kishner B., Guyatt G. A methodological framework for assessing health indices. J. Chronic Dis. 1985; 38: 27–36, [CROSSREF], [CSA]
- Korr W. S., Ford B. C. Measuring quality of life in the mentally ill. Qual. Life Res. 2003; 12: 17–23, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Leidy N. K., Revicki D. A., Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999; 2: 113–27, [CROSSREF], [CSA]
- Little I., Mirrlees J. A. Project Appraisal and Planning for Developing Countries. Heinemann Educational Books, London 1974
- Mendlowicz M. V., Stein M. B. Quality of life in individuals with anxiety disorders. Amer. J. Psych. 2000; 157(5)669–682, [CROSSREF], [CSA]
- Mishan E. J. Cost-benefit Analysis, 3rd ed. George Allen & Unwin Ltd., London 1982
- Muldoon M. F., Barger S. D., Flory J. D., Manuck S. B. What are quality of life measurements measuring?. Br. Med. J. 1998; 316(7130)542–545, [CSA]
- Patrick D. L., Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. Oxford University Press, New York 1993
- Reno R. R., Aiken L. S. Life activities and life quality of heroin addicts in and out of methadone treatment. Int. J. Addict. 1993; 28(3)211–232, [PUBMED], [INFOTRIEVE], [CSA]
- Revicki D. A., Osoba D., Fairclough D., Barofsky I., Berzon R., Leidy N. K. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual. Life Res. 2000; 9: 887–900, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Richman A. Cost/effectiveness analysis of alcoholism and drug abuse treatment programs: the relevance of recidivism and resource absorption. Eval. Program. Plann. 1983; 6(1)49–52, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Salyers M. P., Bosworth H. B., Swanson J. W., Lamb-Pagone J., Osher F. C. Reliability and validity of the SF-12 health survey among people with severe mental illness. Med. Care. 2000; 38(11)1141–50, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schipper H., Clinch J. J., Olweny C. L. Quality of life studies: definitions and conceptual issues. Quality of Life and Pharmacoeconomics in Clinical Trials, B. Spilker. Lippincott-Raven, Philadelphia 1996; 11–24
- Schumacher J. E., Mennemeyer S. T., Milby J. B., Wallace D., Nolan K. Costs and effectiveness of substance abuse treatments for homeless persons. J. Ment. Health Policy Econ. 2002; 5(1)33–42, [PUBMED], [INFOTRIEVE], [CSA]
- Sindelar J. L., Jofre-Bonet M., French M. T., McLellan A. T. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes. Drug. Alcohol. Depend. 2004; 73(1)41–50, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vanagas G., Bagdonas E., Padaiga Z. Cost analysis in economic evaluation of methadone maintenance treatment: a methodological approach. Drug Alcohol Abuse 2004; 17(1–2)21–28, 2004[CSA]
- Vanagas G., Padaiga Z., Subata E. Economic efficiency of the methadone maintenance and factors affecting it. Medicina (Kaunas) 2004; 40(7)607–613, [CSA]
- Vanagas G., Padaiga Z., Subata E. Drug addiction maintenance treatment and quality of life measurements. Medicina (Kaunas) 2004; 40(9)833–841, 2004[CSA]
- Ventegodt S., Merrick J. Psychoactive drugs and quality of life. Scientific World Journal 2003; 3(8)694–706, [PUBMED], [INFOTRIEVE], [CSA]
- Walker D. How to do (or not to do) … Cost and cost-effectiveness guidelines: which ones to use?. Health Policy Plan 2001; 16: 113–121, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ware J. E. Methodological considerations in the selection of health status assessment procedures. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies, N. Wenger. MMFCEJ La Jacq, Greenwich 1984; 87–111
- Wilkin D., Hallam L., Doggett M. A. Measures of Need and Outcome for Primary Health Care. Oxford University Press, Oxford 1992